Laura Carzaniga
Laura Carzaniga has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Andrea Rizzi
Chiesi Farmaceutici, Corporate Preclinical R&D, Research Center, Largo Belloli 11/A, 43122 Parma, Italy
7 shared publicationsGino Villetti
Chiesi Farmaceutici S.p.A, Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy
7 shared publicationsMaurizio Civelli
Chiesi Farmaceutici S.p.A, Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy
7 shared publicationsRiccardo Patacchini
AIR Franchise, Chiesi Farmaceutici S.p.A., Research Center, Largo Belloli 11/a, 43122 Parma, Italy
7 shared publicationsValentina Mileo
Chiesi Farmaceutici S.p.A Largo Belloli 11/a
7 shared publicationsMaurizio Delcanale
Chemistry Research and Drug Design Department, Chiesi Farmaceutici S.p.A, Research Center, Largo Belloli 11/a, 43122 Parma, Italy
6 shared publications
Latest Publications
- 20 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 25128-25150
Lung-Tailored Pyrrolo-pyrimidine DDR Inhibitors Designed for Optimized Local Delivery
Preclinical studies highlighted the key role of Discoidin Domain Receptors (DDRs) in fibrotic processes, making them promising targets for Idiopathic Pulmonary Fibrosis (IPF) treatment. In this work, we describe the design of a novel class of DDR inhibitors and their subsequent optimization toward inhaled delivery. Following a structure-based approach, we identified two chemical series based on 5:6 heterocyclic cores showing nanomolar affinity for DDR1 and DDR2 and a promising kinome selectivity profile. An inhaled-by-design medchem strategy was then applied to optimize potency, phys-chem, and in vitro ADME properties, tailored to achieve lung-restricted compounds. This effort resulted in the discovery of compound 25, a novel and highly potent DDR inhibitor that combined antifibrotic activity in a TGFβ-induced in vitro fibrosis model with an outstanding pharmacokinetic profile and the desired lung-targeted behavior following inhaled administration.
- 20 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 25128-25150
Lung-Tailored Pyrrolo-pyrimidine DDR Inhibitors Designed for Optimized Local Delivery
Preclinical studies highlighted the key role of Discoidin Domain Receptors (DDRs) in fibrotic processes, making them promising targets for Idiopathic Pulmonary Fibrosis (IPF) treatment. In this work, we describe the design of a novel class of DDR inhibitors and their subsequent optimization toward inhaled delivery. Following a structure-based approach, we identified two chemical series based on 5:6 heterocyclic cores showing nanomolar affinity for DDR1 and DDR2 and a promising kinome selectivity profile. An inhaled-by-design medchem strategy was then applied to optimize potency, phys-chem, and in vitro ADME properties, tailored to achieve lung-restricted compounds. This effort resulted in the discovery of compound 25, a novel and highly potent DDR inhibitor that combined antifibrotic activity in a TGFβ-induced in vitro fibrosis model with an outstanding pharmacokinetic profile and the desired lung-targeted behavior following inhaled administration.
- 30 September 2026
- Published by Springer Nature in Nature Reviews Drug Discovery
- p. 1-34
Soft drugs: design principles and topical applications
The rational design of soft drugs has emerged as a powerful strategy to enhance drug safety, without compromising efficacy. Unlike conventional active pharmaceutical ingredients, soft drugs are deliberately designed to undergo predictable and rapid metabolic inactivation after exerting their therapeutic effect. Systemic soft drugs are particularly valuable in anaesthesiology, where rapid offset of action is desirable. Regarding topical administration, the soft drug approach enables potent local activity while minimizing systemic exposure and toxicity. However, despite these advantages and the market approval of several soft drugs, especially in dermatological, inhaled and gut-restricted therapies, the concept remains underutilized and often misunderstood, frequently being conflated with prodrugs. This Review revisits the concept of soft drugs from a modern perspective, clarifies its distinction from related approaches, highlights recent clinical successes in topical delivery, and provides practical insights into the application of soft drug design in drug discovery.
- 30 September 2026
- Published by Springer Nature in Nature Reviews Drug Discovery
- p. 1-34
Soft drugs: design principles and topical applications
The rational design of soft drugs has emerged as a powerful strategy to enhance drug safety, without compromising efficacy. Unlike conventional active pharmaceutical ingredients, soft drugs are deliberately designed to undergo predictable and rapid metabolic inactivation after exerting their therapeutic effect. Systemic soft drugs are particularly valuable in anaesthesiology, where rapid offset of action is desirable. Regarding topical administration, the soft drug approach enables potent local activity while minimizing systemic exposure and toxicity. However, despite these advantages and the market approval of several soft drugs, especially in dermatological, inhaled and gut-restricted therapies, the concept remains underutilized and often misunderstood, frequently being conflated with prodrugs. This Review revisits the concept of soft drugs from a modern perspective, clarifies its distinction from related approaches, highlights recent clinical successes in topical delivery, and provides practical insights into the application of soft drug design in drug discovery.
- 20 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6610-6633
A Journey through Scaffolds: Indolines, Pyrrolidines, and Azetidines in the Quest for Inhaled DDR Inhibitors for IPF
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, with excessive Extracellular Matrix (ECM) deposition impairing gas exchange, leading to lung failure. Current treatments are limited, with lung transplantation as the only cure. Discoidin Domain Receptors (DDR1/2), collagen-activated receptor tyrosine kinases, orchestrate collagen deposition in fibrotic diseases. We report the discovery and optimization of novel DDR1/2 kinase-domain inhibitors suitable for inhaled administration. Starting from a benzylamine scaffold, three chemical series, namely indolines, pyrrolidines, and azetidines, were explored. The first two showed potent DDR1 inhibition and lung retention but faced safety and selectivity challenges. The azetidine compound 37 was identified as the most promising one for its nanomolar potency, improved kinase selectivity, reduced cardiotoxicity risk, and excellent inhaled PK profile. It demonstrated activity in a collagen-induced pharmacodynamic mouse model, supporting its potential as an inhaled DDR inhibitor for IPF and validating the azetidine scaffold as a promising starting point for further optimization.
- 20 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6610-6633
A Journey through Scaffolds: Indolines, Pyrrolidines, and Azetidines in the Quest for Inhaled DDR Inhibitors for IPF
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, with excessive Extracellular Matrix (ECM) deposition impairing gas exchange, leading to lung failure. Current treatments are limited, with lung transplantation as the only cure. Discoidin Domain Receptors (DDR1/2), collagen-activated receptor tyrosine kinases, orchestrate collagen deposition in fibrotic diseases. We report the discovery and optimization of novel DDR1/2 kinase-domain inhibitors suitable for inhaled administration. Starting from a benzylamine scaffold, three chemical series, namely indolines, pyrrolidines, and azetidines, were explored. The first two showed potent DDR1 inhibition and lung retention but faced safety and selectivity challenges. The azetidine compound 37 was identified as the most promising one for its nanomolar potency, improved kinase selectivity, reduced cardiotoxicity risk, and excellent inhaled PK profile. It demonstrated activity in a collagen-induced pharmacodynamic mouse model, supporting its potential as an inhaled DDR inhibitor for IPF and validating the azetidine scaffold as a promising starting point for further optimization.
- Open Access
- 7 April 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (5) , 784-789
Macrocyclization: Enhancing Drug-like Properties of Discoidin Domain Receptor Kinase Inhibitors
Macrocyclization, a well-established strategy for developing ligands against challenging drug targets, was employed to design macrocyclic alternatives to a linear discoidin domain receptor (DDR) inhibitor (1) with potential applications in treating fibrotic diseases. This study aimed to enhance the drug-like profile of 1 through innovative design strategies encompassing molecular docking and chameleonicity considerations. These efforts resulted in the synthesis of matched pairs of macrocycles differing in flexibility and linker features. Compound 5a emerged as a promising lead, exhibiting nanomolar-range activity, significantly improved solubility, and excellent permeability. Comprehensive experimental physicochemical characterization further highlighted the modest impact of ionization, the major role played by lipophilicity (but not polarity) in driving permeability of the investigated matched pairs, and the limitations of traditional 2D computational descriptors in predicting macrocycle ADME-related properties.
- 7 April 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (5) , 784-789
Open AccessMacrocyclization: Enhancing Drug-like Properties of Discoidin Domain Receptor Kinase Inhibitors
Macrocyclization, a well-established strategy for developing ligands against challenging drug targets, was employed to design macrocyclic alternatives to a linear discoidin domain receptor (DDR) inhibitor (1) with potential applications in treating fibrotic diseases. This study aimed to enhance the drug-like profile of 1 through innovative design strategies encompassing molecular docking and chameleonicity considerations. These efforts resulted in the synthesis of matched pairs of macrocycles differing in flexibility and linker features. Compound 5a emerged as a promising lead, exhibiting nanomolar-range activity, significantly improved solubility, and excellent permeability. Comprehensive experimental physicochemical characterization further highlighted the modest impact of ionization, the major role played by lipophilicity (but not polarity) in driving permeability of the investigated matched pairs, and the limitations of traditional 2D computational descriptors in predicting macrocycle ADME-related properties.
- 5 December 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2444-2465
Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease
The design of inhaled selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors for the treatment of inflammatory lung diseases was pursued. Knowledge-based design of a novel isocoumarin scaffold that was able to adopt a propeller-shape topology ensured the desired PI3Kδ selectivity. Achievement of low nanomolar cellular potencies through hinge binder group optimization, reduction of intrinsic permeability through head group optimization to extend lung retention, and screening of crystalline forms suitable for administration as dry powders culminated in the identification of compound 18. This novel inhaled selective PI3Kδ inhibitor displayed durable anti-inflammatory activity in a disease-relevant rat model of Th-2-driven acute lung inflammation and safe in vitro and in vivo preclinical profiles. Therefore, compound 18 showed the appropriate discovery profile and was progressed to clinical trials in healthy volunteers and chronic obstructive pulmonary disease (COPD) patients as CHF-6523.
- 5 December 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2444-2465
Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease
The design of inhaled selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors for the treatment of inflammatory lung diseases was pursued. Knowledge-based design of a novel isocoumarin scaffold that was able to adopt a propeller-shape topology ensured the desired PI3Kδ selectivity. Achievement of low nanomolar cellular potencies through hinge binder group optimization, reduction of intrinsic permeability through head group optimization to extend lung retention, and screening of crystalline forms suitable for administration as dry powders culminated in the identification of compound 18. This novel inhaled selective PI3Kδ inhibitor displayed durable anti-inflammatory activity in a disease-relevant rat model of Th-2-driven acute lung inflammation and safe in vitro and in vivo preclinical profiles. Therefore, compound 18 showed the appropriate discovery profile and was progressed to clinical trials in healthy volunteers and chronic obstructive pulmonary disease (COPD) patients as CHF-6523.
- 10 June 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (12) , 9816-9841
Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases
Clinical guidelines for COPD and asthma recommend inhaled beta-adrenergic agonists, muscarinic antagonists, and, for frequent exacerbators, inhaled corticosteroids, with the challenge of combining them into a single device. The MABA (muscarinic antagonist and beta(2) agonist) concept has the potential to simplify this complexity while increasing the efficacy of both pharmacologies. In this article, we report the outcome of our solid-state driven back-up program that led to the discovery of the MABA compound CHF-6550. A soft drug approach was applied, aiming at high plasma protein binding and high hepatic clearance, concurrently with an early stage assessment of crystallinity through a dedicated experimental workflow. A new chemotype was identified, the diphenyl hydroxyacetic esters, able to generate crystalline material. Among this class, CHF-6550 demonstrated in vivo efficacy, suitability for dry powder inhaler development, favorable pharmacokinetics, and safety in preclinical settings and was selected as a back-up candidate, fulfilling the desired pharmacological and solid-state profile.
- 10 June 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (12) , 9816-9841
Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases
Clinical guidelines for COPD and asthma recommend inhaled beta-adrenergic agonists, muscarinic antagonists, and, for frequent exacerbators, inhaled corticosteroids, with the challenge of combining them into a single device. The MABA (muscarinic antagonist and beta(2) agonist) concept has the potential to simplify this complexity while increasing the efficacy of both pharmacologies. In this article, we report the outcome of our solid-state driven back-up program that led to the discovery of the MABA compound CHF-6550. A soft drug approach was applied, aiming at high plasma protein binding and high hepatic clearance, concurrently with an early stage assessment of crystallinity through a dedicated experimental workflow. A new chemotype was identified, the diphenyl hydroxyacetic esters, able to generate crystalline material. Among this class, CHF-6550 demonstrated in vivo efficacy, suitability for dry powder inhaler development, favorable pharmacokinetics, and safety in preclinical settings and was selected as a back-up candidate, fulfilling the desired pharmacological and solid-state profile.
- 28 July 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (15) , 10233-10250
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases
The development of molecules embedding two distinct pharmacophores acting as muscarinic antagonists and β2 agonists (MABAs) promises to be an excellent opportunity to reduce formulation issues and boost efficacy through cross-talk and allosteric interactions. Herein, we report the results of our drug discovery campaign aimed at improving the therapeutic index of a previous MABA series by exploiting the super soft-drug concept. The incorporation of a metabolic liability, stable at the site of administration but undergoing rapid systemic metabolism, to generate poorly active and quickly eliminated fragments was pursued. Our SAR studies yielded MABA 29, which demonstrated a balanced in vivo profile up to 24 h, high instability in plasma and the liver, as well as sustained exposure in the lung. In vitro safety and non-GLP toxicity studies supported the nomination of 29 (CHF-6366) as a clinical candidate, attesting to the successful development of a novel super-soft MABA compound.
- 28 July 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (15) , 10233-10250
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases
The development of molecules embedding two distinct pharmacophores acting as muscarinic antagonists and β2 agonists (MABAs) promises to be an excellent opportunity to reduce formulation issues and boost efficacy through cross-talk and allosteric interactions. Herein, we report the results of our drug discovery campaign aimed at improving the therapeutic index of a previous MABA series by exploiting the super soft-drug concept. The incorporation of a metabolic liability, stable at the site of administration but undergoing rapid systemic metabolism, to generate poorly active and quickly eliminated fragments was pursued. Our SAR studies yielded MABA 29, which demonstrated a balanced in vivo profile up to 24 h, high instability in plasma and the liver, as well as sustained exposure in the lung. In vitro safety and non-GLP toxicity studies supported the nomination of 29 (CHF-6366) as a clinical candidate, attesting to the successful development of a novel super-soft MABA compound.
- Open Access
Preparation of Sterically Demanding 2,2-Disubstituted-2-Hydroxy Acids by Enzymatic Hydrolysis
Preparation of optically-pure derivatives of 2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetic acid of general structure 2 was accomplished by enzymatic hydrolysis of the correspondent esters. A screening with commercial hydrolases using the methyl ester of 2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetic acid (1a) showed that crude pig liver esterase (PLE) was the only preparation with catalytic activity. Low enantioselectivity was observed with substrates 1a–d, whereas PLE-catalysed hydrolysis of 1e proceeded with good enantioselectivity (E = 28), after optimization. Enhancement of the enantioselectivity was obtained by chemical re-esterification of enantiomerically enriched 2e, followed by sequential enzymatic hydrolysis with PLE. The preparation of optically-pure (S)-2e was validated on multi-milligram scale.
Open AccessPreparation of Sterically Demanding 2,2-Disubstituted-2-Hydroxy Acids by Enzymatic Hydrolysis
Preparation of optically-pure derivatives of 2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetic acid of general structure 2 was accomplished by enzymatic hydrolysis of the correspondent esters. A screening with commercial hydrolases using the methyl ester of 2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetic acid (1a) showed that crude pig liver esterase (PLE) was the only preparation with catalytic activity. Low enantioselectivity was observed with substrates 1a–d, whereas PLE-catalysed hydrolysis of 1e proceeded with good enantioselectivity (E = 28), after optimization. Enhancement of the enantioselectivity was obtained by chemical re-esterification of enantiomerically enriched 2e, followed by sequential enzymatic hydrolysis with PLE. The preparation of optically-pure (S)-2e was validated on multi-milligram scale.
- 14 December 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (24) , 10026-10046
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases
Phosphodiesterase 4 (PDE4) is a key cAMP-metabolising enzyme involved in the pathogenesis of inflammatory disease and its pharmacological inhibition has been shown to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD). Herein we describe a drug discovery program aiming at the identification of novel classes of potent PDE4 inhibitors suitable for pulmonary administration. Starting from a previous series of benzoic acid esters, we explored the chemical space in the solvent-exposed region of the enzyme catalytic binding pocket. Extensive structural modifications led to the discovery of a number of heterocycloalkyl esters as potent in vitro PDE4 inhibitors. (S*,S**)-18e and (S*,S**)-22e, in particular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependently counteracted acute lung eosinophilia in an experimental animal model. The optimal biological profile as well as the excellent solid state properties suggest that both compounds have the potential to be effective topical agents for treating respiratory inflammatory diseases.
- 14 December 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (24) , 10026-10046
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases
Phosphodiesterase 4 (PDE4) is a key cAMP-metabolising enzyme involved in the pathogenesis of inflammatory disease and its pharmacological inhibition has been shown to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD). Herein we describe a drug discovery program aiming at the identification of novel classes of potent PDE4 inhibitors suitable for pulmonary administration. Starting from a previous series of benzoic acid esters, we explored the chemical space in the solvent-exposed region of the enzyme catalytic binding pocket. Extensive structural modifications led to the discovery of a number of heterocycloalkyl esters as potent in vitro PDE4 inhibitors. (S*,S**)-18e and (S*,S**)-22e, in particular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependently counteracted acute lung eosinophilia in an experimental animal model. The optimal biological profile as well as the excellent solid state properties suggest that both compounds have the potential to be effective topical agents for treating respiratory inflammatory diseases.